NCT00500500View on ClinicalTrials.gov

Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

PHASE2TerminatedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Alzheimer Disease

Interventions

DRUG

EGb 761® (Tanakan®)

Trial Locations (1)

13 005

Hôpital La Timone, Marseille

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Ipsen

INDUSTRY